Cargando…

Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series

The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhaliwal, Armaan, Ravi, Soumiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550779/ https://www.ncbi.nlm.nih.gov/pubmed/37809221 http://dx.doi.org/10.7759/cureus.44677

Ejemplares similares

Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series
por: Dhaliwal, Armaan, et al.
Publicado: (2023)

The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
por: Wang, Yang, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
por: Miyao, Kotaro, et al.
Publicado: (2023)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
por: Lipe, Demis N., et al.
Publicado: (2023)

Increased Circulating of CD54(high)CD181(low) Neutrophils in Myelodysplastic Syndrome
por: Yang, Liyan, et al.
Publicado: (2021)

Anti-CD19 chimeric antigen receptor T-cell followed by interferon−α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report
por: Ni, Jing, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis
por: Jang, Jong Keon, et al.
Publicado: (2022)

Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis
por: Chen, Li-Rong, et al.
Publicado: (2022)

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
por: Burns, Ethan A., et al.
Publicado: (2021)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review
por: Feng, Gang, et al.
Publicado: (2021)

Abnormal Ferroptosis in Myelodysplastic Syndrome
por: Lv, Qi, et al.
Publicado: (2020)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
por: Marzal-Alfaro, María Belen, et al.
Publicado: (2021)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

The enigma of persistent hypertriglyceridemia: A case report
por: Dhaliwal, Armaan, et al.
Publicado: (2022)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
por: Ye, Mingyu, et al.
Publicado: (2022)

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
por: Chen, Panpan, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Editorial: Risk-stratification in myelodysplastic syndromes
por: Breccia, Massimo, et al.
Publicado: (2022)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Prognostic Value of Radiomic Features of (18)F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells
por: Zhou, Yeye, et al.
Publicado: (2022)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v71r3nk4hh3tus01e7a8fm1buh